Optimizing the Size of Micellar Nanoparticles for Efficient siRNA Delivery. (25th June 2015)

• Record Type: Journal Article
• Authors: Liang, Shi; Yang, Xian‐Zhu; Du, Xiao‐Jiao; Wang, Hong‐Xia; Li, Hong‐Jun; Liu, Wei‐Wei; Yao, Yan‐Dan; Zhu, Yan‐Hua; Ma, Yin‐Chu; Wang, Jun; Song, Er‐Wei
• Is Part Of: Advanced functional materials. Volume 25:Number 30(2015)
• Page Start: 4778
• Page End: 4787
• Publication Date: 2015-06-25
• Subjects: cancer therapy -- drug delivery -- nanocarriers -- siRNA -- size effect; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adfm.201501548
• Languages: English
• ISSNs: 1616-301X

Abstract

Abstract : Delivery of small interfering RNA (siRNA) by nanocarriers has shown promising therapeutic potential in cancer therapy. However, poor understanding of the correlation between the physicochemical properties of nanocarriers and their interactions with biological systems has significantly hindered its anticancer efficacy. Herein, in order to identify the optimal size of nanocarriers for siRNA delivery, different sized cationic micellar nanoparticles (MNPs) (40, 90, 130, and 180 nm) are developed that exhibit similar siRNA binding efficacies, shapes, surface charges, and surface chemistries (PEGylation) to ensure size is the only variable. Size‐dependent biological effects are carefully and comprehensively evaluated through both in vitro and in vivo experiments. Among these nanocarriers, the 90 nm MNPs show the optimal balance of prolonged circulation and cellular uptake by tumor cells, which result in the highest retention in tumor cells. In contrast, larger MNPs are rapidly cleared from the circulation and smaller MNPs are inefficiently taken up by tumor cells. Accordingly, 90 nm MNPs carrying polo‐like kinase 1 (Plk1)‐specific siRNA (siPlk1) show superior antitumor efficacy, indicating that 90 nm could either be the optimal size for systemic delivery of siRNA or close to it. Our findings provide valuable information for rationally designing nanocarriers for siRNA‐based cancer therapy in the future. Abstract : To investigate the optimal size of nanocarriers for siRNA delivery, different sized MNP/siRNAs are rationally designed. Size‐dependent biological effects on circulation, internalization, retention, and overall antitumor efficacy are carefully and comprehensively evaluated. These results indicate that 90 nm could be at or close to the optimal size for systemic delivery of siRNA.